Format

Send to

Choose Destination
Rheumatology (Oxford). 2016 Feb;55(2):301-6. doi: 10.1093/rheumatology/kev323. Epub 2015 Sep 8.

Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up.

Author information

1
Internal Medicine Department and.
2
Culture and Cell Therapy Laboratory, INSERM CBT-1409, Assistance Publique Hôpitaux de Marseilles, Aix-Marseilles University.
3
Centre d'Investigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques, Assistance Publique Hôpitaux de Marseilles.
4
Plastic Surgery Department.
5
Department of Dermatology and.
6
Hematology and Vascular Biology Laboratory, Assistance Publique Hôpitaux de Marseilles and Vascular Research Center Marseille, INSERM UMRS-1076, Aix-Marseilles University, Marseilles, France.
7
Culture and Cell Therapy Laboratory, INSERM CBT-1409, Assistance Publique Hôpitaux de Marseilles, Aix-Marseilles University, Hematology and Vascular Biology Laboratory, Assistance Publique Hôpitaux de Marseilles and Vascular Research Center Marseille, INSERM UMRS-1076, Aix-Marseilles University, Marseilles, France.
8
Centre d'Investigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques, Assistance Publique Hôpitaux de Marseilles, Plastic Surgery Department.
9
Internal Medicine Department and Vascular Research Center Marseille, INSERM UMRS-1076, Aix-Marseilles University, Marseilles, France bgranel@ap-hm.fr.

Abstract

OBJECTIVE:

Impaired hand function greatly contributes to disability and reduced quality of life in SSc patients. Autologous adipose-derived stromal vascular fraction (ADSVF) is recognized as an easily accessible source of regenerative cells. We reported positive 6-month safety and efficacy results from an open-label clinical trial assessing s.c. injection of autologous ADSVF into the fingers in SSc patients. The objective of this report is to describe the effects at 12 months.

METHODS:

Twelve females, mean age 54.5 years (s.d. 10.3), were assessed 1 year after ADSVF injection. Patients were eligible if they had a Cochin Hand Function Scale score >20/90. ADSVF was obtained from lipoaspirate using an automated processing system and subsequently injected into the s.c. tissue of each finger in contact with neurovascular pedicles in a one-time procedure. Endpoints were changes in hand disability and skin fibrosis, vascular manifestations, pain and quality of life at the 12 month follow-up. During the visit, patients estimated the benefit of the procedure with a specific self-completed questionnaire.

RESULTS:

A significant decrease from baseline of 51.3% (P < 0.001) for Cochin Hand Function Scale score, 63.2% (P < 0.001) for RP severity and 46.8% (P = 0.001) for quality of life (Scleroderma Health Assessment Questionnaire) was observed. A significant improvement of finger oedema, skin sclerosis, motion and strength of the hands and of the vascular suppression score was also noted. The reduction in hand pain approached statistical significance (P = 0.052). The questionnaire revealed a benefit in daily activities, housework and social activities.

CONCLUSION:

ADSVF injection is a promising therapy and appears to have benefits that extend for at least 1 year.

KEYWORDS:

adipose tissue; cell therapy; hand; stromal vascular fraction; systemic sclerosis

PMID:
26350489
DOI:
10.1093/rheumatology/kev323
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center